Article

Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans.

Department of Medicine, Overton Brooks VAMC, East Stoner Avenue 151 (Research), Shreveport, LA 71101, USA.
Chest (impact factor: 5.25). 05/2007; 131(5):1282-8. DOI:10.1378/chest.06-0931 pp.1282-8
Source: PubMed

ABSTRACT Statins are commonly used cholesterol-lowering agents that are noted to suppress tumor cell growth in several in vitro and animal models.
We studied the association of lung cancer and the use of statins in patients enrolled in the Veterans Affairs (VA) Health Care System. A retrospective case-control study nested in a cohort study was conducted using prospectively collected data from the Veterans Integrated Service Networks 16 VA database from 1998 to 2004. We analyzed data on 483,733 patients from eight states located in south central United States. The primary variables of interest were lung cancer and the use of statins prior to the diagnosis of lung cancer. Multiple logistic regression analysis was done to adjust for covariates including age, sex, body mass index, smoking, diabetes, and race. Statistical software was used for statistical computing.
Of the 483,733 patients in the study, 163,662 patients (33.8%) were receiving statins and 7,280 patients (1.5%) had a primary diagnosis of lung cancer. Statin use > 6 months was associated with a risk reduction of lung cancer of 55% (adjusted odds ratio, 0.45; 95% confidence interval, 0.42 to 0.48; p < 0.01). Furthermore, the protective effect of statin was seen across different age and racial groups and was irrespective of the presence of diabetes, smoking, or alcohol use.
Statins appear to be protective against the development of lung cancer, and further studies need to be done to define the clinical utility of statins as chemo protective agents.

0 0
 · 
0 Bookmarks
 · 
15 Views
  • Source
    Article: Statins in esophageal cancer cell lines: promising lead?
    Ernest T Hawk, Jaye L Viner
    [show abstract] [hide abstract]
    ABSTRACT: Barrett's-associated esophageal adenocarcinoma (BEAC) is an important health concern in many western populations owing to its increasing incidence and the paucity of effective treatments. Statins have recently been suggested to induce anticancer effects against a variety of cancers in several, but not all, in vitro, in vivo, and epidemiologic studies. In the accompanying article by Ogunwobi and Beales, three statins were shown to inhibit proliferation and stimulate apoptosis in two EAC cell lines. These effects were achieved by reducing Ras, extracellular signal-regulated kinase (ERK), and protein kinase B (Akt)-related cellular signaling. Although these results are promising, they are clearly preliminary, and much additional work is needed to confirm or refute the potential anticancer effects of statins in human BEAC. In addition, the work of Ogunwobi and Beales highlights the importance of developing better, more predictive in vitro and in vivo models of BEAC, and of taking promising, low-risk agents, such as statins, into early-phase therapeutic and preventive clinical trials involving cancer patients and patients with Barrett's metaplasia/dysplasia, respectively.
    The American Journal of Gastroenterology 05/2008; 103(4):838-41. · 7.28 Impact Factor
  • Source
    Article: Pleiotropic effects of the HMG-CoA reductase inhibitors
    CG Mihos, O Santana
    [show abstract] [hide abstract]
    ABSTRACT: Christos G Mihos, Orlando SantanaColumbia University Division of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, USAAbstract: The HMG-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropy of statins and emphasizes the importance of randomized placebo-controlled trials to further elucidate this interesting phenomenon.Keywords: HMG-CoA inhibitors, pleiotropic, reductase, review, statins
    International Journal of General Medicine. 01/2011;
  • Source
    Article: Pleiotropic effects of the HMG-CoA reductase inhibitors.
    Christos G Mihos, Orlando Santana
    [show abstract] [hide abstract]
    ABSTRACT: The HMG-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropy of statins and emphasizes the importance of randomized placebo-controlled trials to further elucidate this interesting phenomenon.
    International Journal of General Medicine 01/2011; 4:261-71.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

95% confidence interval
 
alcohol use
 
animal models
 
body mass index
 
chemo protective agents
 
cholesterol-lowering agents
 
cohort study
 
different age
 
lung cancer
 
Multiple logistic regression analysis
 
odds ratio
 
primary variables
 
protective effect
 
retrospective case-control study nested
 
risk reduction
 
Statin use
 
statins
 
tumor cell growth
 
Veterans Affairs
 
Veterans Integrated Service Networks 16 VA database